EQ504
Asset
Multi-cytokine inhibitor targeting immunomodulatory pathways
- Stage
- Phase 1
- Modality
- Peptide
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Inflammatory diseases
Phase 1, globenewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.